TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Gill S, Gowda L, Uberti J, Buonomo E, Wang Y, Nabilsi N, White T, Nguyen C, Murray J, MacBeath G, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial. Blood 2024, 144: 924. DOI: 10.1182/blood-2024-201526.Peer-Reviewed Original ResearchReduced intensity conditioningRelapse-free survivalPost-HCTDonor chimerismTreatment armsFollow-upControl armMalignant lineagesGrade 2-4 acute graft-versus-host diseaseT cell receptor-engineered T cellsControl subjectsIncreased relapse-free survivalGraft-versus-host diseaseMedian time to relapseControl arm subjectsNon-relapse deathPost-HCT MRDComplete donor chimerismDonor-derived cellsEngineered T cellsMedian follow-upTime to relapseCD3+ cellsPhase 1 studyARMS subjects